SCHEMBL6017791

SCHEMBL6017791

Cc1ccc(CNC(=O)c2nc(-c3ccccc3N(C)C)n(C)c(=O)c2O)cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNE1 P15382 1/20 0.39
CCR1 P32246 1/20 0.39
KCNQ1 P51787 1/20 0.39
MMP1 P03956 1/20 0.38
MMP7 P09237 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
TSHR P16473 1/20 0.37
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
EGLN1 Q9GZT9 1/20 0.36
THRB P10828 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017747 0.92 CNR1 (0.40) KCNE1CCR1KCNQ1MMP1MMP7
SCHEMBL6018460 0.89 CNR1 (0.46) ALDH1A1POLBMEN1KMT2A
SCHEMBL6018587 0.88 SMN1; SMN2 (0.51) KCNE1CCR1KCNQ1POLBSMN1; SMN2
SCHEMBL6017731 0.86 KCNE1 (0.37) KCNE1CCR1KCNQ1MMP1MMP7
SCHEMBL6017780 0.85 MEN1 (0.41) KCNE1CCR1KCNQ1MMP1MMP7
SCHEMBL6017795 0.85 MMP1 (0.50) KCNE1CCR1KCNQ1MMP1MMP7
SCHEMBL6018060 0.85 TSHR (0.47) KCNE1CCR1KCNQ1TSHRALDH1A1
SCHEMBL6017765 0.81 ALDH1A1 (0.41) KCNE1CCR1KCNQ1MMP1MMP7
SCHEMBL6017820 0.81 PIK3CD (0.41) ALDH1A1EGLN1KMT2ANPC1
SCHEMBL6017674 0.80 SMN1; SMN2 (0.42) KCNE1CCR1KCNQ1MMP1MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS KCNE1 3647/4885CCR1 1187/4885KCNQ1 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.